Several factors, including prior/current therapies, epigenetic factors [5, 6], anatomic location of distant metastases [5], as well as variation in tumour dedifferentiation [7] and in the stromal component [8], may influence PSMA expression. The gene discussed is FOLH1; the disease is neoplasm.